New cause of COVID-19 blood clots identified
Covid-19 roundup: Russian biotech seeks permission to produce remdesivir generic; Why did BARDA fund plasma company part-owned by Rick Santorum?
Regeneron, Lilly Setbacks Raise Questions on the Effectiveness of Antibodies in Severe COVID-19
BDX Inks Deal With Dutch Gov. For 9M Covid-19 Antigen Tests
All Eyes on Moderna's COVID-19 Vaccine Ahead of Data Readout
US COVID-19 Cases Top 9 Million, Belgium Announces 6-Week National Lockdown: Live Updates
Covid-19 roundup: Flush with $486M contract, AstraZeneca signs Lonza up to manufacture antibodies; BioNTech's Ugur Sahin expects vaccine data 'in a fortnight'
Eli Lilly Nabs $312.5M US Army Contract For Covid-19 Treatment
Astrazeneca Scores $286.9M US Army Contract For Covid Vaccine
Moderna banks $1.1bn in COVID-19 vaccine deposits, signs Japan supply deal
Regeneron posts second look on Covid-19 antibody cocktail, boosting its case for EUA — but what about symptom alleviation?
The Unjoined Debate
Healthcare And Biotech Outlook –Final Quarter of 2020
UH and CWRU announce study of AstraZeneca’s COVID-19 vaccine candidate
Moderna Scores $1.1B From Covid-19 Vaccine Deposits; Shares Rise 3%
Remdesivir for COVID-19: FDA approved but still unproven
Eli Lilly Strikes $375M Covid-19 Antibody Supply Deal With US Government
Gilead Q3 revenue rise bolstered by $873m Veklury sales
Covid-19 roundup: Boehringer pulls a drug out of the pipeline for a PhII Covid-19 trial; Novavax delays PhIII trial in US, with PhII data coming Friday
Pfizer or Merck: Which Pharma Stock Has More Upside Potential?
Regeneron’s Covid-19 antibody treatment cut medical visits in trial
Miniature organs help test potential coronavirus drugs; GI symptoms linked to severe Covid-19
Gilead cuts 2020 sales outlook as Covid-19 drug remdesivir falls short
Commentary: In the race for a COVID-19 vaccine, how do we balance risk and safety?
These 3 Penny Stocks Could Rack up Triple-Digit Gains, Says Leerink
Pfizer Enters Final Stretch of Late-Stage Covid-19 Vaccine Trial
Covid-19 roundup: Boehringer pulls a drug out of the pipeline for a PhII Covid-19 trial; Novavax delays PhIII trial in US, with PhII data coming Friday;
Covid-19 roundup: Novavax delays PhIII trial in US, with PhII data coming Friday; CBER director promises 'safe and effective' vaccine in op-ed
The COVID "Casedemic" & Biden's "Dark Winter" Plan
US Hospitalizations Soar Almost 40% In One Week; Wisconsin Sees New COVID-19 Record: Live Updates